Adaptive Biotechnologies Q4 revenue beats estimates

Adaptive Biotechnologies

05/02/2026 21:20

Overview

Biotechnology firm's Q4 revenue rose 51% yr/yr, beating analyst expectations

Adjusted EBITDA for Q4 turned positive, exceeding analyst estimates

MRD business achieved positive adjusted EBITDA and cash flow

Outlook

Adaptive Biotechnologies expects MRD revenue between $255 mln and $265 mln for 2026

Company projects operating expenses between $350 mln and $360 mln for 2026

Adaptive Biotechnologies aims to expand margins and achieve profitability in 2026

Result Drivers

MRD REVENUE GROWTH - MRD business revenue increased 54% in Q4, contributing 86% of total revenue

EXPANDED COVERAGE - Expanded Medicare coverage for clonoSEQ test in mantle cell lymphoma

DATA PARTNERSHIPS - Signed two non-exclusive immune receptor data licensing agreements with Pfizer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$71.68 mln
$59.39 mln (7 Analysts)
Q4 EPS
-$0.09
Q4 Net Income
-$13.58 mln
Q4 Adjusted EBITDA
Beat
$4.10 mln
-$7.45 mln (5 Analysts)
Q4 Operating Expenses
$84.45 mln
Q4 Operating Income
-$12.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $20.00, about 15.6% above its February 4 closing price of $17.30

Press Release: ID:nGNXpXjcn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)